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1. Introduction 
It has been known for a long time that programmed cell 
death (PCD) plays an essential role in the formation of a 
multicellular, differentiated animal [1]. A striking example is 
the development of the nematode Caenorhabditis elegans. The 
fully formed animal consists of 1089 cells, of which 131 are 
programmed to die. This system has provided a breakthrough 
in understanding of the molecular processes underlying PCD. 
Indeed, genetic studies first revealed the presence of genes 
needed for PCD, such as ced-3 and ced-4, as well as other 
genes, such as ced-9, which counteract PCD [2]. In addition 
to its role in development, PCD occurs prominently in various 
immune processes, such as negative selection of T-cells in the 
thymus, elimination of overactivated lymphocytes in the pe-
riphery, etc. But PCD—or lack of it—has especially become a 
focus of considerable interest because of its relevance to many 
diseases [3]. For example, cancer cells have often become re-
sistant to PCD-inducing stimuli, various lympho-proliferative 
and/or autoimmune diseases evade 'death' signals, etc. On the 
other hand, in some neuro-degenerative disorders such as Par-
kinson, Alzheimer or amyotrophic lateral sclerosis, one may 
wish to interfere with PCD. 
Cells dying in the course of development are in fact fairly 
difficult to study, because the cell corpses are rapidly phago-
cytosed by neighbouring cells. Therefore, morphological and 
biochemical processes associated with PCD can best be 
studied in cell culture systems, and the typical events leading 
to cell death are usually referred to as 'apoptosis'. 'PCD' and 
'apoptosis' are often used interchangeably, although the for-
mer has more a connotation of genetically predetermined, 
while the latter is more linked to morphological and biochem-
ical changes [4]. The principal characteristics of apoptosis are 
blebbing of the plasma membrane, phosphatidylserine exter-
nalization, cytoskeletal disruption, accumulation and/or acti-
vation of transglutaminase, condensation of nuclear chroma-
tin, fragmentation of nuclear DNA to approximately 50 kb 
segments, and subsequently to internucleosomal fragments; at 
later stages, cytoplasm and nucleus become compartmental-
ized and form membrane-bound apoptotic bodies, which are 
engulfed by neighbouring cells or infiltrated tissue macro-
phages [4]. Cell death by apoptosis is a very neat way to 
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eliminate unwanted cells: no traces are left and the cell con-
tents are never released or accessible to the immune system. 
Hence, there is no inflammation. This is in contrast to death 
by necrosis. Under these conditions, normally the cell swells 
and then, when membrane integrity comes under attack, the 
cell collapses like a balloon and the contents spill out into the 
extracellular milieu [5]. This may result in an inflammatory 
response. 
Although PCD is sometimes referred to as 'cell suicide', in 
most systems studied the process of apoptosis is initiated by 
external inducers or treatments. Some examples are UV- or y-
irradiation, heat shock, oxidative stress, chemotherapeutic 
drugs (directed to topoisomerases like etoposide, to protein 
kinases like staurosporine, to DNA or its building blocks 
like nitrogen mustard and methotrexate, respectively, etc.), 
viral infection, loss of matrix attachment, glucocorticoids, 
growth factor withdrawal, soluble or membrane-bound cyto-
kines like TNF or Fas/Apo-1 (CD95) ligand, and many 
others. In general, each cell contains precursors to apoptogen-
ic mediators, as well as counteracting, protecting proteins. It 
is the balance between these two which determines the out-
come after a given stimulus. It is remarkable how morpholog-
ically and biochemically similar apoptotically dying cells are, 
almost irrespective not only of the cell type, but also of the 
species. This suggests already that the molecular mechanisms 
of apoptosis are ubiquitous in nature and highly conserved in 
evolution. Indeed, various lines of evidence point to a univer-
sal, biochemical pathway. For example, the human anti-apop-
totic protein Bcl-2 (to be discussed in a later section) can 
partially restore a defective ced-9 function in C. elegans 
[6,7]. Equally important, in most systems of apoptosis exper-
imentally studied, clear evidence for involvement of caspases 
was found. Caspases are a recently discovered, extended fam-
ily of Cysteine-type proteases, which cleave after an aspartic 
acid residue; the C. elegans CED-3 protein and interleukin-
1 P-converting enzyme (ICE) are typical examples. Strong evi-
dence for the involvement of caspases is the fact that usually 
the process of apoptosis can be interfered with by specific 
caspase inhibitors, such as zVAD-fmk or viral antagonistic 
pseudo-substrates (see below). 
TNF and Fas/Apo-1 ligand play a prominent role in a 
variety of immunological, inflammatory and pathological con-
ditions. Therefore, many studies on PCD have been done with 
TNF-R55 (CD120a) and Fas/Apo-1-induced death. Both re-
ceptors contain near their intracellular C-terminus a homolo-
gous region of about 90 amino acids, referred to as the 'death 
domain' (DD). Upon clustering, this DD is sufficient for sig-
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nailing cell death. TNF-R55-DD in addition leads to activa-
tion of the transcription factor N F - K B and to gene induction. 
Many of the induced genes are important for inflammation 
(IL-6, IL-8, ICAM-1, E-selectin), while activation of N F - K B is 
also involved in synthesis of resistance proteins, such as A20 
[8]. Recently, other receptors of the same family have been 
cloned and shown to contain a DD-related sequence, such as 
DR3/WSL-1/TRAMP [9-11], chicken CAR-1 [12] and DR4 
[13]. 
2. The TNF ligand and receptor families 
The TNF receptor and ligand families are currently the 
object of intense research, covering a variety of different as-
pects of cellular signalling (reviewed in [14-20]). These ligand 
and receptor families, although large and continuing to in-
crease in size, display rather homogeneous patterns of the 
structures involved in recognition. All members of the recep-
tor family recognize their ligands through a shared sequence 
motif, a repetitive cysteine-rich structure found in different 
numbers in their extracellular domains. All but one of the 
ligands, viz. nerve growth factor (NGF), recognize their re-
ceptors through a shared structure composed of antiparallel p-
strands, arranged in a 'P-jelly roll' topology. These similarities 
of structure are reflected in similar mechanisms of recognition 
and triggering. Apparently all members of the TNF ligand 
family occur and act in trimeric forms, allowing each ligand 
molecule to bind and cluster three receptors. Indeed, all TNF/ 
NGF family members are activated as a consequence of jux-
taposition of several receptor molecules and can thus be arti-
ficially triggered by their cross-linking with antibodies. Anoth-
er common feature of the TNF ligand family is that they all 
act not only as soluble molecules, but also in association with 
the surface of their producing cells. Most of these ligands are 
produced as type-II transmembrane cell surface proteins from 
which the soluble forms are derived proteolytically. The only 
exception, lymphotoxin LT-cc, although formed as a soluble 
secretable protein, can bind, as a subunit, to another member 
of the family, LT-P, and thus also acts as a cell-bound ligand. 
In contrast to the rather homogeneous patterns of amino 
acid sequences and protein structures involved in ligand re-
ceptor recognition, the amino acid sequences of the mtracel-
lular domains of the TNF receptor family appear largely un-
related. This initially gave rise to the false impression that the 
receptors possess unrelated functions and mechanisms of ac-
tion. With the increasing molecular understanding of the sig-
nalling by these receptors it was realized that this impression 
was wrong. It was realized, for example, that some previously 
undetected similarities of sequence exist between the mtracel-
lular domains. There appears to be even greater similarity of 
structure which is not reflected in sequence similarity, since a 
number of receptors with apparently dissimilar intracellular 
domain sequences have turned out to be capable of binding 
the same signalling molecules. In addition, there seems to be 
rather intense cross-talk between the different receptors 
through interaction of different signalling molecules that 
bind to them. These close interactions are reflected in a 
much greater similarity of function than was initially recog-
nized. 
This functional similarity also applies to the ability of the 
receptors of the family to trigger cytocidal effects. Detailed 
information about this activity is restricted mainly to the cy-
tocidal function of TNF-R55, which signals to TNF cytotox-
icity, and Fas/Apo-1, which signals to the cytocidal effect of 
Fas/Apo-1 ligand. Growing evidence indicates, however, that 
such effects can also be triggered by other receptors of the 
family. These include the two other TNF receptors known: 
TNF-R75 (CD 120b), whose cytotoxic signalling [21,22] re-
portedly plays an important role in the self-destruction of 
activated CD8 lymphocytes (more so than that of TNF-
R55) [23], and the LT-P receptor (which binds the complex 
formed between LT-a and LT-P) [24], and also DR3/WSL-1/ 
TRAMP (a receptor closely related to TNF-R55) [9-11], the 
low-affinity NGF receptor [25,26], CD40 [27,28], and others. 
In this review we discuss the cytotoxicity induced by TNF-
R55 and Fas/Apo-1, as these are the only receptors whose 
cytocidal function is at least partially understood at the mo-
lecular level. 
3. Receptor-associated proteins involved in induction of 
cytotoxicity 
In line with the multiplicity of functions mediated by TNF, 
there is growing evidence that the intracellular domain of 
TNF-R55, which signals for many of these activities, has 
the ability to bind and activate a variety of different signalling 
molecules. It is now known that the intracellular domain of 
Fas/Apo-1 also binds a number of different proteins. Most of 
the knowledge of these proteins and their function has been 
gained indirectly, for example by two-hybrid analysis of their 
interactive properties in transfected yeast, or by assessment of 
the interaction of the proteins when expressed in transfected 
cells at supra-physiological levels. The physiological relevance 
of the observations should therefore be carefully evaluated. 
A major aid to assess the relevance of TNF-R55- and Fas/ 
Apo-1-binding proteins to their cytocidal function was ob-
tained when a distinct region involved in death induction 
was delineated within the receptor. As mentioned in Section 
1, this homologous DD is about 90 amino acid residues long 
and was initially defined by exclusion. Whereas mutations 
within this region prevented death induction, mutations up-
stream or downstream of it had no such effect [29-31]. Pos-
itive evidence came from later experiments showing that cel-
lular expression of transfected cDNA encoding this region 
alone is sufficient for death induction [32]. In the case of 
TNF-R55, clustering of the C-terminal domain, containing 
only 101 amino acids, was sufficient to elicit a full cytotoxic 
response and also N F - K B activation [33]. There are no se-
quence motifs in the DD that might allow it to exert direct 
cell-killing, enzymatic action. Moreover, several other pro-
teins, some of them evidently unrelated to cell death induc-
tion, were also found to contain a similar domain [34]. The 
DD exerts its effects via interactive properties. As part of 
some proteins it was found to self-associate and also to be 
capable of binding to DDs in other proteins [35]. Preliminary 
data suggest that it can also bind proteins that do not contain 
a DD. The tendency of the DD in TNF-R55 and Fas/Apo-1 
to self-associate apparently fortifies the interactions of recep-
tor molecules imposed by ligand binding. Following their self-
association, the DDs in the two receptors recruit and bind 
other DD-containing proteins, which serve as adapters in 
the signalling cascades. This binding is apparently made pos-
sible by exposure of the relevant regions in the receptors; 
these regions, according to mutational and NMR studies of 
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the DD in Fas/Apo-1, seem to be partly distinct from those 
involved in self-association of the receptors [36]. Fas/Apo-1 
recruits a DD-containing adapter protein called MORT1/ 
FADD [37,38], and TNF-R55 recruits a DD-containing 
adapter protein called TRADD [39]. Mutational studies indi-
cate that the region upstream of the DD in MORT1/FADD is 
required for death induction by Fas/Apo-1 as well as by TNF-
R55 [40,41]; moreover, since the DDs in MORT1/FADD and 
TRADD can bind to each other, it is assumed (so far with no 
direct evidence) that TNF-R55, when inducing death, recruits 
not only TRADD, but also its associated MORT1/FADD 
molecules. An additional DD-containing protein, called RIP 
[42], can also bind to TRADD as well as to MORT1/FADD 
[35]. It can also bind to a fourth DD-containing molecule 
called RAIDD [43] or CRADD [44], which in turn can inter-
act with CASP-2 (CASP is a standard abbreviation for casp-
ase). The observation that, upon overexpression, at least some 
of these proteins interact even in vivo, suggests that also they 
could be involved in a TNF-induced cascade of signalling to 
cell death. 
Death induction is by no means the only function of the 
DDs in TNF-R55 and Fas/Apo-1. Detailed evidence impli-
cates, for example, the DD of TNF-R55 in activation of 
N F - K B through its sequential interaction with TRADD and 
an adapter protein called TRAF2 (e.g., [41]). Conversely, de-
spite the compelling evidence for a key role of the DD of the 
receptors in death induction, we cannot exclude the possibility 
that proteins associated with other regions in the intracellular 
domains contribute to the overall pattern of the death pro-
gramme. There is already evidence for one such protein, viz. a 
protein tyrosine phosphatase, FAP-1, that binds to Fas/Apo-1 
downstream of its DD and suppresses death induction by a 
mechanism still to be clarified [45]. 
Current notions of the function of signalling molecules ac-
tivated by receptors of the TNF/NGF family are often based 
on tests that have certain shortcomings. The functional con-
sequence of overexpression of a transfected protein may not 
be identical to that of the protein in a more physiological 
concentration. Overexpressed mutants may interfere with cel-
lular functions by a mechanism that does not reflect a dom-
inant negative effect, but rather events such as scavenging of 
other signalling proteins. It is therefore important to validate 
our concepts of the initial events in the signalling cascades by 
applying the acquired knowledge to analysis of what really 
occurs further downstream. In the case of cell death mecha-
nisms, the immediate downstream event seems to be activa-
tion of specific caspases. 
4. The caspases 
As alluded to in Section 1, mutational studies of genes that 
control developmental cell death in nematodes [46] and the 
marked sequence homology observed between one of the 
genes identified in this way, ced-3 [47], and a mammalian 
cysteine protease, ICE [48,49], recently opened the way to 
one of the most intensely studied aspects of current research 
on death mechanisms. Pursuant studies led to the identifica-
tion of a whole family of proteases homologous to CED-3 
and ICE which are widely expressed in mammalian cells. 
Although differing somewhat in exact substrate specificity, 
all of these proteases cleave proteins downstream of aspartate 
residues. They were accordingly dubbed 'caspases', for 
cysteinyl aspartate-specific proteinase [50]. All caspases are 
synthesized as inactive precursors or zymogens. The precursor 
polypeptide consists of a prosequence (or a more complex 
prodomain in the case of CASP-8 and CASP-10), followed 
by a domain of approximately 20 kDa, often a small linker, 
and a domain of approximately 10 kDa. The prosequence is 
required for dimerization of the precursor [51]. Hetero- and/or 
auto-processing then leads to the formation of mature, tetra-
meric (p20)2(pl0)2 [52]. Growing evidence points to a key role 
of caspases in a variety of different apoptotic processes (re-
viewed in [53-56]). There is even a tendency nowadays to 
consider that for a cell death process to occur in a pro-
grammed manner, caspase involvement is a prerequisite. 
Several lines of evidence support the involvement of casp-
ases in cell death induction by TNF and Fas/Apo-1: 
(i) Receptor-induced cell death can be blocked by synthetic 
inhibitors of caspases. It can also be effectively blocked by 
two virus-produced proteins that act as caspase inhibitors, 
viz. the poxvirus serpine CrmA and the baculovirus p35 pro-
tein [57-60]. 
(ii) Caspases are produced as inactive precursors. As in 
other PCD processes, induction of cell death by TNF and 
Fas/Apo-1 has been found to result in rapid activation of 
certain caspases through their proteolytic processing [61-63]. 
(iii) Similarly, several proteins that serve as caspase sub-
strates and have been shown to be cleaved in other apoptotic 
processes were also found to be cleaved at early stages of the 
death processes induced by TNF or Fas/Apo-1 [61,64-66]. 
As opposed to the rather solid evidence that caspases play 
an important role in processes of death induction, information 
about the nature of this role is still fragmentary. Also limited 
is information on the mechanisms of activation of caspases in 
the onset of the cell death process. Another major aspect of 
caspase function in which our knowledge is limited is the 
identity of the substrate proteins cleaved by caspases. Many 
of these substrates are presumably involved in the final events 
leading to apoptotic cell death (to be discussed in Section 6). 
Another aspect of caspase action of which we have only 
partial understanding is the functional significance of their 
multiplicity in mammalian cells [55,56,67]. Although they 
share significant sequence homology, there are also clear dif-
ferences of sequence between the caspases, enabling their clas-
sification into three distinct evolutionary groups. These differ-
ences are particularly pronounced in the regions upstream of 
the protease moieties (the 'prodomain' region). Growing evi-
dence indicates that the prodomain regions regulate caspase 
activation and that their sequence heterogeneity allows acti-
vation of different caspases by different inducers. The most 
compelling evidence for this notion comes from studies of the 
way in which caspases are activated by TNF-R55 and Fas/ 
Apo-1. 
Attempts to uncover the mechanism by which TNF-R55 
and Fas/Apo-1 trigger caspase action have led to the identi-
fication of three caspases whose prodomains can bind to 
adapter proteins interacting with these receptors. The prodo-
mains of CASP-8 (MACH/FLICE/Mch5) [37,68,69] and 
CASP-10 (Mch4/FLICE2) [69,70] were both found to contain, 
in duplicates, a motif termed 'death effector domain' (DED) 
or the 'MORT' motif (also found upstream of the DD in 
MORT1/FADD), and to interact with MORT1/FADD 
through hetero-association of the DED motifs in the proteins. 
In fact, CASP-8 was cloned by screening for proteins that 
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interact with Fas/Apo-1 through MORT1/FADD. CASP-2 
(ICH-1) was similarly found to interact through its prodo-
main with a homologous sequence in a protein called RAIDD 
[43] or CRADD [44]. The latter contains, downstream of its 
caspase-binding site, a DD that binds to the DD of RIP. 
Recruitment of CASP-2, CASP-8 and CASP-10 to the re-
ceptors presumably results in their activation. Once activated, 
they are believed to be capable of processing and activating 
one or more of the other caspases found in the cell, thus 
triggering the death programme [71-73]. It should be stressed, 
however, that at present the evidence for this scenario is 
rather fragmentary. Overexpression of non-functional mu-
tants of CASP-8 (in three cell lines) [37] or of CASP-10 (in 
one of the three) [70] was found to block both Fas/Apo-1- and 
TNF-induced death, suggesting that these two caspases play a 
crucial role in initiating the cytocidal effects of both receptors. 
CASP-8 was indeed shown to be recruited to Fas/Apo-1 upon 
triggering of this receptor [68,74]. So far, however, there is no 
evidence for its recruitment to TNF-R55, or for the recruit-
ment of CASP-10 to either of the two receptors. Neither is 
there any evidence for involvement of CASP-2-RAIDD/ 
CRADD interaction in TNF-R55 or Fas/Apo-1 action. 
In cells that are resistant to Fas/Apo-1 -induced cytotoxicity, 
these receptors are sometimes found to be incapable of re-
cruiting MORT1/FADD and CASP-8 [74]. The molecular 
modifications that control the recruitment process are not 
known. A possible clue to their nature was provided by recent 
studies showing that CED-4, a death-regulatory protein in 
nematodes, can bind to the nematode caspase CED-3 and 
simultaneously to CED-9, a nematode homologue of Bcl-2, 
which can block cell death (cf. Section 5.3) [75,76]. Moreover, 
CED-4 was also found to be capable of binding to CASP-8, 
suggesting the possible existence of a mammalian CED-4 ho-
mologue that controls CASP-8 action by binding to it [75]. 
Many viruses have developed a strategy to avoid premature 
suicide of the infected cell. One example is expression of fac-
tors which interfere upstream in TNF-signalling and Fas/Apo-
1-signalling interactions (dominant negative effectors) [77,78]. 
A second example are caspase pseudo-substrates which are 
powerful inhibitors of these enzymes, such as CrmA [79] 
and p35 [80]. A third class are factors which mimic the Bcl-
2-type anti-apoptotic activity [81-83]. Similar factors of cellu-
lar origin may exist and modulate the apoptosis/anti-apopto-
sis balance; also molecules related to signal transduction fac-
tors, and formed for example by alternative splicing, may 
affect positively or negatively the final outcome [84,85]. 
5. Involvement of mitochondria and Bcl-2 family members 
in cell death 
5.1. General 
Early studies on apoptosis mainly focused on the nuclear 
events, which were indeed dramatic: DNA fragmentation and 
apoptotic body formation. But later on, the premise that the 
key steps in apoptosis occur in the nucleus was challenged. 
Removal of nuclei from cells still allowed induction of typical 
apoptotic events in the anucleate cytoplasts treated with anti-
Fas/Apo-1 or staurosporine [86,87]. On the other hand, it has 
long been suspected that mitochondria play a key role in 
TNF-induced cell death. This hypothesis was tested by isolat-
ing cells devoid of mitochondrial DNA, and hence of a func-
tional oxidative phosphorylation chain. In the case of TNF-
induced necrosis, these cells were protected (see below), but 
they were still susceptible to (staurosporine-induced) cell 
death [87,88]. However, the latter experiments do not exclude 
a crucial role of mitochondria; indeed, mitochondrial proteins 
in mammalia are mainly nuclear-encoded, and cell lines lack-
ing mitochondrial DNA and oxidative phosphorylation still 
contain mitochondria-like structures. These mitochondrial, 
DNA-deficient organelles maintain their membrane potential, 
and possibly could respond to triggers by the release of apop-
togenic factors [89]. A second suggestion that mitochondria 
play a pivotal role in apoptosis follows from the localization 
of anti-apoptotic Bcl-2 family members. Bcl-2 is localized in 
the outer mitochondrial membrane, but also in the nuclear 
membrane and the endoplasmic reticulum. The main mecha-
nism of action of Bcl-2 at the level of mitochondria will be 
discussed below (Section 5.3). The essential role of mitochon-
dria was further revealed more directly by reconstructed, acel-
lular systems of apoptotic processes. It is generally believed 
that the evident role of mitochondria is not a direct conse-
quence of disruption of their energy-supplying function. In 
fact, RNA and protein synthesis usually continue unabated 
right until the onset of cell death. 
5.2. Mitochondria-derived reactive oxygen intermediates 
(ROI): involvement in cytotoxicity 
Matthews was the first to report that at least some types of 
cells treated with TNF showed gross abnormalities in the 
structure of their mitochondria; they looked swollen and 
had fewer cristae [90]. Furthermore, TNF-induced cell death 
was almost abrogated when the cells were kept in anaerobio-
sis, indicating a dependence on oxygen for cytotoxicity. In 
HEK293 or ME-180 cells, Wong et al. obtained protection 
by overexpression of mitochondrial manganous superoxide 
dismutase [91]. These results indicate that superoxide is 
formed as a result of TNF action and contributes directly 
to the cytotoxicity. MnSOD, which in many cells is induced 
by TNF, can be considered as a protective protein. However, 
these results cannot be generalized. In many other cell types, 
expression of MnSOD does not confer protection. 
In early studies, including those of L. Old and colleagues 
[92], the tester cell line of choice was often the fibrosarcoma-
derived L-cell line. Upon treatment with TNF, L929 cells die 
by necrosis [5] (it may be noted that there exist also L929 lines 
which die by apoptosis). In the case of necrotic death of L929 
cells, the evidence that ROI are directly responsible for cyto-
toxicity is substantial. For example, the cells could be pro-
tected almost completely by preventing the electron flow from 
mitochondrial complex I and II to complex III, using the 
inhibitors amytal and thenoyltrifluoroacetone, respectively 
[93]. TNF treatment caused the formation of weird ultrastruc-
tural changes in the mitochondria of L929 cells. L929 sub-
lines, selected on the basis of loss of mitochondrial DNA, 
became almost completely resistant to TNF-induced cytotox-
icity. This is not in contradiction to the aforementioned state-
ment that functional mitochondria-deficient cells were still 
susceptible to staurosporine-induced cell death, because in 
the latter system cell death proceeded by release of apopto-
genic factors, as will be discussed below, while in L929 cells 
necrosis is due to ROI, which for their formation depend on 
electron flow to oxygen [94]. TNF leads to enhanced ROI 
production by the mitochondria, which can be quantitated 
on a per-cell basis [95]. Only some scavengers can efficiently 
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protect the cells from ROI. Presumably the reason is that they 
need to be present in the hydrophobic area where the ROI are 
formed; the most efficient is butylated hydroxyanisole (BHA). 
Addition of BHA to TNF-treated L929 cells almost immedi-
ately abrogates excess ROI formation and prevents further 
necrotic cell death [95]. The real target of the ROI effect which 
leads to the demise of the cell is not known; it may be some 
particular protein(s) or particular membrane peroxidation. 
Although L929 is an especially striking example of TNF-in-
duced necrosis via ROI intermediates, it is certainly not an 
exception; there are many examples of tumour cell killing by 
ROI upon TNF treatment [96,97], and also some other agents 
can elicit ROI-dependent cell death [98,99]. 
5.3. Mitochondrial permeability transition and modulation by 
Bcl-2 family members 
In many cells undergoing apoptosis, a fairly drastic drop in 
mitochondrial transmembrane potential (A*Pm) is observed. A 
drop in A ^ is due to permeability transition which allows 
small molecules (<1500 Da) to leak out from the matrix 
[100]. This permeability transition is induced by nearly all 
stimuli which cause apoptosis, including TNF and anti-Fas/ 
Apo-1. It is believed that the fall in A*Fm is a point of no 
return in the pathway to cell death [100]. What are the mo-
lecular events causing permeability transition? The precise 
molecular mechanism is still not clear, but a mass of evidence 
suggests that Bcl-2 and homologues are physiological regula-
tors of permeability transition, and therefore an understand-
ing of their mode of action is essential. 
Bcl-2 was originally discovered by its overexpression in B-
cell lymphoma/leukemia 2. In addition, Bcl-2 is frequently 
found to be (over)expressed in various carcinomas, lympho-
mas and leukemias, and is thought to play an important role 
in resistance to therapy [101-103]. Both Bcl-2 and its homo-
logue BC1-XL are well expressed in embryonic tissues; in the 
adult, Bcl-2 is expressed in rapidly dividing cells, but not, for 
example, in the central nervous system, where only Bcl-x is 
expressed. Bax is another homologous protein which forms 
heterodimers with Bcl-2 and prevents the anti-apoptotic func-
tion of the latter. It seems quite likely that, at least in some 
tissues, the well-known tumour suppressor gene p53 exerts its 
function by induction of Bax [104]. It is of interest that over-
expression of Bax can even cause death of yeast cells, but only 
under conditions where they require functional mitochondria 
[105]. In addition to CED-9 mentioned above, the Bcl-2/Bcl-
XL family further includes Bcl-W, Al and Mcl-1 which, under 
appropriate conditions, can prevent apoptosis. On the other 
hand, the pro-apoptotic members include, in addition to Bax, 
Bik, Bak, Bad and Bcl-xg (reviewed in [106]). Many viruses 
express anti-apoptotic functions, and some of these mimic 
Bcl-2. A striking example is the adenovirus E1B-19K protein, 
which only shows a minimal homology to Bcl-2, yet fulfils a 
similar anti-apoptotic function [81,102]. Bcl-2 and BC1-XL oc-
cur in the mitochondrial outer membrane, in the endoplasmic 
reticulum and in the nuclear membrane, but we have men-
tioned already that Bcl-2 can protect from PCD even in the 
absence of a nucleus [107]. Its occurrence on the mitochon-
drial membrane is rather patchy, suggesting interaction with 
special structures. Bcl-2 and homologues have a hydrophobic 
tail required for membrane association. Removal of this tail 
leads to cytosolic Bcl-2, which is far less effective in preventing 
apoptosis. 
How does Bcl-2 promote cell survival? We have mentioned 
before that permeability transition and loss of ATm represent 
an irreversible step in the pathway to apoptosis. Hence, if Bcl-
2 or BC1-XL protect cells, they must do so at a step before 
permeability transition, as has indeed been experimentally 
verified. In addition to form dimers with homologous family 
members, Bcl-2 also associates with the protein kinase Raf-1, 
and in this way drags Raf-1 to the mitochondrial membrane 
[108]. There, Bad becomes phosphorylated, resulting in its 
binding to the adapter protein 14-3-3, rather than to BC1-XL, 
thus blocking the pro-apoptotic function of Bad [109,110]. 
Also, Bcl-2 may itself become inactivated by phosphorylation 
[111]. However, the kinase responsible for phosphorylation of 
Bcl-2 and Bad is not Raf-1 itself. The modulating effects of 
protein phosphorylation on pro- and anti-apoptotic effects 
(Bcl-2 and Bax, respectively) have been recently reviewed 
[112]. 
More information on the presumed mechanism of action of 
Bcl-2 and homologues has come from recent structural stud-
ies. The 3D-structure of BC1-XL was shown to be similar to the 
structure of the pore-forming domains of bacterial toxins 
[113]. Indeed, BC1-XL can insert into lipid bi-layers and form 
cation-selective, ion-conducting channels [114]. Although this 
is the first demonstration of a physiological function of a Bcl-
2 member, it is not yet proven that this property is responsible 
for the anti-apoptotic effect. Neither is there an attractive 
model which would explain how such a pore-forming mole-
cule could prevent, for example, mitochondrial permeability 
transition. 
What then is the trigger which causes the mitochondrial 
membrane transition pore formation, and which is counter-
acted by Bcl-2 and homologues? As we have mentioned be-
fore, a variety of apoptogenic stimuli converge to effect the 
collapse of the mitochondrial membrane potential. The signal-
ling pathway emanating from TNF or anti-Fas/Apo-1 trigger-
ing can be inhibited by CrmA and zVAD-fmk, specific inhib-
itors of caspases. It is conceivable that the activated CASP-8 
released from the receptor complex or downstream-activated 
caspases could directly act on the mitochondria. In fact, im-
portant new findings support such a hypothetical scenario. 
And this evidence comes again from the elegant C. elegans 
system. In this organism, it is well known that in addition to 
CED-3 there is also a requirement for the protein of the ced-4 
gene in order to execute cell death. The mammalian homo-
logue of CED-4 has so far not been found. But recently it was 
discovered that the CED-9 protein, presumably localized in 
the mitochondria, physically interacts with CED-4, which it-
self interacts with CED-3. Mutational analysis indicates that 
this binding correlates with functionality [76,115]. Moreover, 
CED-4 can also physically interact with mammalian CASP-1 
and CASP-8. In this way, a possible link between the mito-
chondria and the receptor-signalling system of Fas/Apo-1 and 
TNF-R55 has been established [38]. It is also of interest to 
note that, although several pathways leading to apoptosis 
converge at the events occurring at the mitochondrial mem-
brane, which often can be inhibited by Bcl-2, the upstream 
requirement for caspases is not a universal phenomenon. For 
example, signals to mitochondria that are coming from the 
TNF receptor or from Fas/Apo-1 are blocked, as mentioned 
above, by caspase inhibitors, while the pathways stimulated 
by irradiation, by chemotherapeutic drugs or by peroxide are 
not affected [116]. 
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5.4. Mitochondria-driven steps in signalling 
After Fas/Apo-1 cross-linking, activation of CASP-1-like 
enzymes precedes CASP-3-like activation and nuclear apopto-
sis. Inhibition of this CASP-3 activity prevents the down-
stream terminal phase, during which various substrates are 
cleaved. CASP-3 and homologues exist in a precursor form 
in the cytosol, and require proteolytic activation for function-
ing. The role of the mitochondria in this activation is not yet 
known in detail, but some interesting observations have been 
made using cell-free systems. Lazebnik et al. [117] were the 
first to show that it was possible to make an extract from cells 
in the condemned phase of apoptosis, which could induce in 
isolated nuclei morphological and biochemical features that 
were typical of a nucleus in an apoptotically dying cell. Par-
allel studies with Xenopus oocyte extracts showed that an 
essential component responsible for caspase activation and 
apoptotic effects in cell-free extracts was in fact the mitochon-
dria [118]. Fractionation of the apoptogenic extract revealed 
that there are at least two factors required for CASP-3 acti-
vation, one of which, surprisingly, was cytochrome c [119]. By 
itself, cytochrome c cannot cleave or activate recombinant 
CASP-3 in vitro. It is likely that it interacts with (a) pre-ex-
isting cytoplasmic factor(s) which subsequently mediate(s) the 
cleavage of zymogens. Cells undergoing apoptosis were found 
to have elevation of cytochrome c in the cytosol and a corre-
sponding decrease in the mitochondria. Overexpression of 
Bcl-2 or even exogenous addition of recombinant Bcl-2 to 
isolated mitochondria prevented the efflux of cytochrome c 
[120]. Remarkably, cytochrome c release was unaccompanied 
by changes in A*Fm [116]. It is interesting to note that in C. 
elegans the messenger coding for CED-9 is in fact polycis-
tronic and also leads to synthesis of a cytochrome-Z>560-re-
lated protein [7]. Another factor, also released from mitochon-
dria, gives a better view of how it could initiate CASP-3-like 
activation. It has been reported that mitochondrial permeabil-
ity transition also results in a Bcl-2-inhibitable release of a 
~ 50 kDa intermembrane protein that was sufficient to cause 
nuclear apoptosis [121]. The activity of this protein, referred 
to as AIF or 'apoptosis-inducing factor', was inhibited by 
zVAD-fmk, but not by any of the other caspase inhibitors. 
Moreover, AIF causes CASP-3 activation in vitro, connecting 
the mitochondrial phase of apoptosis with a downstream 
caspase activation pathway. Whether cytochrome c is a co-
factor in this process or whether it is involved in a parallel 
pathway, is at present unknown. 
6. Caspase substrates and their involvement in the final events 
of the apoptotic process 
6.1. General 
The end of the apoptotic process is characterized by a com-
mon degradation phase during which cells acquire the bio-
chemical and morphological features of end-stage apoptosis. 
While the morphological changes are quite well characterized, 
the biochemical basis for these dramatic events is still unclear, 
although caspases seem to play an important role also at this 
stage. 
Four kinds of caspase substrates, each mediating a distinct 
set of functions, can generally be distinguished: (i) the first 
caspase substrate to be identified was the IL-lp precursor, 
cleaved by ICE (CASP-1); processing of this precursor (and 
other substrates of the same category [122-124]) is not in-
volved in apoptosis, but rather contributes to the induction 
of inflammation; (ii) there is considerable evidence that auto-
processing plays an important role in activation and matura-
tion of caspases [52]; furthermore, at least some of the 
caspases are involved in a cascade of sequential activation 
[71,72]; (iii) structural proteins, such as lamin or actin, the 
cleavage of which is likely to contribute to the disassembly 
of cellular structures during the death process; (iv) other pro-
teins with a variety of activities. Some of the proteins of the 
last group have enzymatic activities that may help to repair 
damage in the dying cell. It has been suggested that their 
cleavage, and subsequent inactivation, results in enhancement 
of the death process [125]. Since none of the proteins found to 
be cleaved by caspases has been shown to serve a vital func-
tion, it is difficult to understand how the activation of these 
enzymes results in cell death. Our current knowledge of the 
identity of the caspase substrates is based solely on chance 
identification. A systematic analysis of the pattern of caspase 
substrates may be required in order to determine how the 
activities of these proteases contribute to the induction of 
death and the extent to which their contribution is assisted 
by other activities, induced independently by the TNF recep-
tors and Fas/Apo-1. 
6.2. Nuclear changes 
As mentioned in Section 1, the nuclear events of apoptosis 
include chromatin condensation, DNA fragmentation to do-
main-sized fragments (30-50 and 200-300 kb) and then to 
oligonucleosomes (180-200 bp), cleavage of specific target 
proteins, and ultimately budding of nuclei into membrane-
enclosed apoptotic bodies. Several endonucleases have been 
proposed to be involved in the degradation of DNA during 
apoptosis (for a review on nucleases in apoptosis, see [126]). 
One of the nuclear proteins which is cleaved during apoptosis 
is the DNA repair-associated enzyme, poly(ADP-ribose) pol-
ymerase (PARP) [127]. Enzymes which can cleave PARP in-
clude CASP-3, CASP-7, CASP-8 and CASP-9 [55]. The DNA-
dependent protein kinase is another enzyme which is involved 
in DNA repair and which is also cleaved by CASP-3-like 
proteases [128]. CASP-6 cleaves the nuclear lamins [129], in-
termediate filament proteins that form a meshwork beneath 
the inner nuclear membrane and provide a framework for the 
attachment of chromatin to the nuclear envelope. Because this 
meshwork is important for the stability of the nuclear enve-
lope, it makes sense that lamin cleavage is required for dis-
assembly of the nucleus into individual apoptotic bodies. An-
other substrate that is cleaved after Fas/Apo-1 and TNF 
treatment, is the 70-kDa component of the Ul small ribonu-
cleoprotein [65]. Cleavage of this protein may play a role in 
regulating RNA splicing and in loss of chromatin organiza-
tion during apoptosis [130]. 
PITSLRE kinases are a superfamily of protein kinases re-
lated to the master mitotic protein kinase, cdc2. Induction of 
apoptosis via the Fas/Apo-1 receptor in human T-cells has 
been shown to be correlated with proteolysis and increased 
activity of PITSLRE kinases [131]. Furthermore, cleavage of 
at least some isoforms of PITSLRE kinases during TNF-in-
duced apoptosis has recently been shown to be mediated by 
CASP-3 or a close homologue [66]. Ectopic expression of the 
smallest member of this superfamily has previously been 
shown to induce apoptosis [132]. In addition, deletion of the 
PITSLRE gene complex and complete loss of expression of 
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Fig. 1. A cartoonist's view of the cell death field. 
specific isoforms occur in many neuroblastoma cell lines and 
are frequently observed in human cancers [133]. Therefore, 
PITSLRE kinases may have a role in the apoptotic effector 
phase, rather than being involved in the final degradation 
phase. Another kinase which has recently been implicated in 
nuclear phenotypic changes associated with apoptosis induced 
by anti-Fas/Apo-1 and TNF is protein kinase C 8. Cleavage 
of the latter by CASP-3 is associated with activation of the 
kinase function [134]. 
6.3. Cytoplasmic changes 
One of the most noticeable morphological features of apop-
tosis is fragmentation of the cell into apoptotic bodies. A 
rearrangement of the microfilament network of the cell must 
occur during this process and may be responsible for some of 
the observed changes. Cleavage of oc-fodrin and actin during 
apoptosis induced by Fas/Apo-1 and several other stimuli has 
been shown to be mediated by caspases [64,135]. Cleavage of 
these structural proteins may be related to the process of 
blebbing observed during the final stages of the apoptotic 
process. 
At the onset of apoptosis there is a large increase in trans-
glutaminase activity which is responsible for cross-linking of 
proteins. This will stabilize the cytoplasm of dying cells, pre-
venting the leakage of harmful and pro-inflammatory or im-
munogenic, intracellular elements into the external milieu. 
6.4. Cell membrane alterations in apoptosis 
During apoptosis, there are extensive cell membrane alter-
ations; the cell detaches from neighbouring cells and from the 
extracellular matrix. In addition, apoptotic cells display cell-
surface markers (e.g., thrombospondin, CD36) that ensure 
their recognition and removal by phagocytic cells. Phagocytic 
receptors also recognize changes in membrane sugars and lip-
id composition (exposure of negatively charged phosphatidyl 
serine on the outer leaflet) [136]. Activation of sphingomye-
linase and the sustained elevation of ceramide levels observed 
after several hours of TNF treatment can be prevented by the 
caspase inhibitor, CrmA [137], suggesting that ceramide may 
function as a downstream effector of apoptosis, rather than as 
an upstream primary signalling switch. 
7. Concluding remarks 
One can afford to propose models when knowledge is com-
prehensive, or when almost nothing is known. In the field of 
cell death research we are now at an intermediate stage, where 
too little is known for detailed models and too much for 
indulgence in pure hypotheses. Allegorically, applying the 
metaphor of the 'black box' often used to represent large 
gaps in knowledge, our current molecular understanding of 
cell death could be portrayed as the emergence of several 
point-light sources that illuminate scattered patches in the 
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black box, but do not yet merge to give a clear view of the 
box as a whole (see Fig. 1). 
Our state of the understanding of death induction by re-
ceptors of the TNF family corresponds to our general state of 
knowledge of PCD. The information on some of the mole-
cules that apparently participate in these common mecha-
nisms is very limited. There is a reason to believe, for exam-
ple, that cellular inhibitor-of-apoptosis proteins (c-IAPs) play 
a role in the control of cell killing by the TNF receptor family. 
Two c-IAPs (c-IAPl and C-IAP2) were found to bind to the 
TNF-R75-associated protein, TRAF2 [138,139], and to be 
recruited with it to TNF-R55 upon receptor activation [140]. 
Little is known, however, about how c-IAPs act and how they 
actually affect TNF cytotoxicity. Another example concerns 
the involvement of specific oncogenes in TNF cytotoxicity. 
There is conclusive evidence that the level of c-Myc expression 
affects cell vulnerability to TNF cytotoxicity, at least in some 
cell systems [141-143]; however, in the absence of information 
on the mechanisms by which c-Myc affects cell viability, this 
information provides no more than a starting point for future 
exploration. 
The focus of this review was on four sources of information 
that did yield significant knowledge about the mechanisms of 
cell death induction. One of them is unique to the study of 
death induced by the TNF receptor family, namely the se-
quential analysis of signalling cascades activated by the recep-
tors. The other three are common to the cell death field: 
studies of the caspases, of the Bcl-2 family, and—presumably 
associated with it—of the changes that occur in the mitochon-
dria during cell death. As described above, each of these di-
rections of research has provided a view of a whole series of 
molecular changes that participate in death induced by Fas/ 
Apo-1 or TNF-R55. The large remaining gaps still leave room 
for doubts as to the validity of our present notions. Gaps are 
particularly noticeable in the zones of overlap between the 
mechanistic domains illuminated by each of the four direc-
tions of research. How, for example, does the signalling cas-
cade initiate the changes that occur in the mitochondria? 
What is the exact contribution of the mitochondrial changes 
and of the Bcl-2 family members to caspase activation? The 
present-day quest for the Holy Grail therefore is directed to 
the identification of the mammalian homologue of the C. 
elegans ced-4 gene product, which may shed more light on 
some of these questions. 
To advance further, it is important to define clearly those 
points requiring elucidation. The extensive phenomenological 
knowledge gained over the 8 years of study of the death proc-
esses activated by Fas/Apo-1 [144,145] and the almost 30 
years of study of death induced by TNF/LT [92,146,147] 
form a solid basis for delineation of the gaps in our under-
standing of the mechanisms involved. Here are a few of the 
questions that may arise when attempting to reconcile these 
old phenomenological data with our current molecular under-
standing: 
(i) The kinetics of death. It was surprising to find that 
CASP-8 and CASP-10 associate directly with the Fas/Apo-1 
and TNF-R55 signalling complexes, and thereby are appar-
ently activated immediately upon triggering of the receptor. 
This finding seems inconsistent with the long-known fact that 
there is a time lag, of at least several hours, between the initial 
triggering of TNF-R55 or Fas/Apo-1 and the death process 
(e.g., [148]). The molecular basis for this gap is unknown. 
(ii) Regulation of sensitivity to the cytocidal activity of the 
receptors. Although the major constituents of the death-sig-
nalling complex have been identified, we still lack understand-
ing of the quantitative determinants of the process. Cells that 
express the same amounts of TNF-R55 or Fas/Apo-1, their 
adapter proteins and the various caspases can differ substan-
tially in their vulnerability to the cytocidal effect of the recep-
tors. Several lines of evidence indicate that this variation in-
volves the activity of 'protective proteins' that render cells 
resistant to the cytocidal effect. Moreover, there are indica-
tions that at least some of these protective proteins are in-
duced by TNF itself through activation of N F - K B , thus ex-
erting a negative feedback control of TNF function (reviewed 
in [149]). Although several TNF-induced proteins capable of 
providing partial resistance in some cells against TNF cyto-
toxicity have been identified [91,150,151], it seems that the 
identity of the major determinants of vulnerability to death 
induction by the receptors still remains to be defined. Further-
more, many malignant cell lines become much more sensitive 
to TNF after co-treatment with IFN-y, and the molecular 
reason for this synergy also escapes us. 
(iii) Relationship between the cell-killing activities of Fas/ 
Apo-1 and TNF-R55. Several comparative studies of cytotox-
icity induction by Fas/Apo-1 and TNF-R55 indicate that, 
despite their close structural similarity, their mechanisms of 
death induction are somewhat different. This is manifested in 
different morphological features and different ways of modu-
lation of the death processes by various pharmacological 
agents and cytokines [152-155]. Such differences were ob-
served, not only when comparing the way death occurs 
upon triggering of the two receptors in different cells, but 
even when death was induced by the two receptors in the 
same cell, suggesting that they reflect differences in the mech-
anisms of action of the two receptors. Our present informa-
tion on the mechanisms of signalling to death provides few 
clues to the nature of this difference. The components of the 
signalling complexes so far found by mutational analysis to be 
specifically involved in the induction of death, namely 
MORT1/FADD, CASP-8 and CASP-10, seem to be equally 
involved in death induction by each of the receptors 
[37,38,41,70]. As mentioned above, clustering of TNF-R55 
leads via TRADD^>Traf2 to rapid N F - K B activation and 
gene induction; but differences between TNF-R55 and Fas/ 
Apo-1 in the phenomena of death induction persist even in the 
presence of protein synthesis inhibitors. 
Perhaps the most important recent lesson of the death-in-
ducing activity of the TNF ligand family is that these media-
tors of immune killer cell function employ the same molecules 
and mechanisms as those involved in all other PCD processes: 
caspases, mitochondrial functions, etc. Thus when the above 
and related questions are investigated, the knowledge gained 
in connection with the cell-killing activity of TNF-R55 and 
Fas/Apo-1 need not necessarily be restricted to this particular 
field, but may promote our understanding of cell death in 
general. 
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